Skip to main content
Fig. 8 | Breast Cancer Research

Fig. 8

From: Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer

Fig. 8

Effects of BAZ1B silencing in combination with Dot1L or menin blockade in antiestrogen-sensitive and antiestrogen-resistant BC cells. A Proliferation rate assessed by MTT assay in AE-sensitive (MCF7) tamoxifen (MCF7 TAM-R)- and fulvestrant/ICI (MCF7 ICI-R)-resistant BC cells following BAZ1B, Dot1L or menin silencing or combining BAZ1B silencing with EPZ B or MI-136 C treatment. Data are presented as the mean ± SD of multiple determinations from a representative experiment performed in multiple replicates. RT-qPCR showing ESR1 (ERα) mRNA level by combining BAZ1B silencing with EPZ D and MI-136 E pharmacological inhibition in the same experimental condition indicated above. RT-qPCR results represent mean ± SD of triplicate determinations from a representative experiment. Asterisks indicate statistically significant differences (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.005) to CTRL or to single treatment (black bars)

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us